[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Diabetic Nephropathy Global Clinical Trials Review, H1, 2019

May 2019 | 401 pages | ID: DA6369378F8EN
GlobalData

US$ 2,500.00

Email Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Diabetic Nephropathy Global Clinical Trials Review, H1, 2019

SUMMARY

GlobalData's clinical trial report, “Diabetic Nephropathy Global Clinical Trials Review, H1, 2019' provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Diabetic Nephropathy
Apr 29, 2019: XORTX provides update on development of diabetic nephropathy drug candidate XRx-221
Apr 26, 2019: Novel therapy Atrasentan hydrochloride slow CKD progression in patients with diabetes
Apr 16, 2019: XORTX shares findings of diabetes study in youths supporting high uric acid advances kidney disease progression
Apr 15, 2019: Goldfinch bio presents data enabling the advancement of innovative approaches to the treatment of kidney disease at the International Society of Nephrology World Congress 2019
Feb 26, 2019: Dimerix provides MX-200 clinical trials update
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019*
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019*
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

LIST OF FIGURES

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019*
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019*
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
GlobalData Methodology

COMPANIES MENTIONED

Pfizer Inc
Mitsubishi Chemical Holdings Corp
Bayer AG
Novartis AG
Eli Lilly and Co
C. H. Boehringer Sohn AG & Co KG
Takeda Pharmaceutical Co Ltd
Steno Diabetes Center Copenhagen
Daiichi Sankyo Co Ltd
AbbVie Inc


More Publications